pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Edurant PED
drug
save

rilpivirine hydrochloride ODT

Marketedupdated 3mo ago
by $JNJ JOHNSON & JOHNSON
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval2 co-mentions · 1 sources
  • drugRILPIVIRINE HYDROCHLORIDE1 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for hiv-1 infection and hiv infection.

all catalysts(1)

approval · 1
Jan 29, 2026
approval
6mo ago
RILPIVIRINE HYDROCHLORIDE — FDA approval
rilpivirine hydrochloride ODT
→

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 15, 2027
216 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (1)

  • Oct 23, 2037formulationUS 11065198

FDA exclusivities (4)

  • Sep 15, 2027PEDPediatric (6mo bonus)1.1y
  • Sep 15, 2027PEDPediatric (6mo bonus)1.1y
  • Mar 15, 2027NPPNew Product (3y)216d
  • Mar 15, 2027NPNP216d

News(0)

no news has mentioned this drug yet

brand
Edurant PED
generic
rilpivirine hydrochloride
MOA
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
indication
Human Immunodeficiency Virus (HIV) Infections (AIDS)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?